Hugo Salmon

Hugo Salmon

Auto-generated profile, based on publicly available information

Hugo Salmon

Université Paris Cité, INSERM UMR-S 1124 (HEALTHFEX), Paris, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
NDNicholas DiStasio
Nicholas DiStasio
HSHugo Salmon
Hugo Salmon
FDFrance Dierick
France Dierick
TETalin Ebrahimian
Talin Ebrahimian
MTMaryam Tabrizian
Maryam Tabrizian
SLStephanie Lehoux
Stephanie Lehoux
The ability to target nanoparticles to the dysfunctional endothelium may present a new and innovative therapy for cardiovascular disease. In this work, an anti‐inflammatory gene therapy nanoparticle targeted to VCAM‐1, a protein overexpressed by inflamed endothelial cells located within atherosclerotic plaque, is developed. Targeting is accomplished via a peptide‐grafted coating for the nanoparticles. Nanoparticle binding to VCAM‐1 is probed via surface plasmon resonance with imaging to determine kinetics and binding dynamics. Targeted nanoparticles are internalized by transfected inflamed primary endothelial cells more than nontargeted controls (80% vs 30% positive cells) under both static and dynamic flow conditions. The nanoparticles also bind specifically to VCAM‐1+ endothelial cells within atherosclerotic plaque from mouse models in both the aortic sinus and whole aorta. Taken together, this nanoparticle formulation may be an effective and specific strategy for anti‐inflammatory therapy within the context of atherosclerosis.

1 August 2014 in Sensors and Actuators A: Physical
Verified
Journal Article
Closed access
GHGilgueng Hwang
Gilgueng Hwang
IIIoan Alexandru Ivan
Ioan Alexandru Ivan
JAJoel Agnus
Joel Agnus
HSHugo Salmon
Hugo Salmon
SASébastien Alvo
Sébastien Alvo
AHAnne-Marie Haghiri-Gosnet
Anne-Marie Haghiri-Gosnet

15 November 2018 in Advanced Materials Technologies
Verified
Journal Article
Closed access
PDF file
JLJulie Lachaux
Julie Lachaux
HSHugo Salmon
Hugo Salmon
FLFanny Loisel
Fanny Loisel
NANassim Arouche
Nassim Arouche
IOIgnacio Ochoa
Ignacio Ochoa
EREmmanuel Roy
Emmanuel Roy

1 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SAShayan Ahmed
Shayan Ahmed
HSHugo Salmon
Hugo Salmon
NDNicholas DiStasio
Nicholas DiStasio
HDHai Doan DO
Hai Doan DO
DSDaniel Scherman
Daniel Scherman
Nathalie MignetNathalie Mignet
Nathalie Mignet
Since its discovery, evidence that siRNA was able to act as an RNA interference effector, led to its acceptation as a novel medicine. The siRNA approach is very effective, due to its catalytic mechanism, but still the limitations of its cellular delivery should be addressed. One promising form of non-viral gene delivery system is liposomes. The variable and versatile nature of the lipids keeps the possibility to upgrade the liposomal structure, which makes them suitable for encapsulation and delivery of drugs. However, to avoid the limitation of fast release for the hydrophilic drug, we previously designed viscous core liposomes. We aimed in this work to evaluate if these viscous core liposomes (NvcLs) could be of interest for siRNA encapsulation. Then, we sought to add a limited amount of positive charges to provide cell interaction and transfection. Cationic lipid dimyristoylaminopropylaminopropyl or the polymer poly(ethylenimine) were incorporated in NvcL to produce positively charged viscous core liposomes (PvcL) by a customized microfluidic device. We found that NvcLs increased the encapsulation efficiency and loading content with regards to the neutral liposome. Both PvcLPEI and PvcLDMAPAP exhibited transfection and GFP knock-down (≈40%) in both 2D and 3D cell cultures. Finally, the addition of slight positive charges did not induce cell toxicity.

1 May 2013
Verified
Conference Paper
Closed access
HSHugo Salmon
Hugo Salmon
LCLaurent Couraud
Laurent Couraud
GHGilgueng Hwang
Gilgueng Hwang
The development of new mobile microrobotic swimmers, limited by low Reynolds dynamics and stiction effects in confined environments, should aim for efficient propulsion mechanisms in wet confined environments and more elaborated manipulation strategies. We first introduced a novel type of microrobots called MagPol (Magnetic Polarizable) integrated in a microfluidic chip controlled through magnetic waves. We developed a simple method analyzing rotational dynamics to characterize swimming performances inside microfluidic environments and provide experimental criteria to improve hydrodynamics of future designs. Magpols demonstrated their in-plane mobilities, with a maximum speed up-to 566 millimeters per second (1390 body lengths per second), and the completions of sophisticated trajectory through the microchannels, forward or backward. In addition to their enhanced planar mobilities, we newly demonstrated a backward towing technique by reversing intrinsic magnetic moment.

31 January 2022 in View
Verified
Journal Article
Open access
PDF file
MPMax Piffoux
Max Piffoux
ASAmanda K. A. Silva
Amanda K. A. Silva
FGFlorence Gazeau
Florence Gazeau
HSHugo Salmon
Hugo Salmon
The clinical interest around extracellular vesicles (EVs) started during the year 2000s, now leading to new clinical diagnostic and therapeutic strategies. Due to their outstanding properties as biogenic drug delivery systems and as alternatives to cell therapy, the need to produce EVs with sufficiently high yield and quality for clinical use expedited the development of analytical techniques and dedicated bioproduction methods. Though preclinical studies revealed the potential of EVs to become next generation subcellular therapies that could lead to major breakthroughs in current therapeutics possibilities, they remain complex objects on both a physicochemical and biological level. Here, we review the capacity of microfluidic technologies to match EV‐based therapeutics need for clinical translation via standardized and intensified bioproduction methods. Indeed, some of the current routine tools used in bioproduction are already achieved on chips such as micromixers or particle sorting and analysis using field flow fraction or nanoparticle tracking analyzer. Also, microfluidics communities have developed a wide set of new techniques to isolate and quantify EVs, but the few that are adopted in a bioproduction workflow are well‐established since the 1990s. We first review the different EV generation and loading methods embedded on chip. We focus on EVs preparation methods, from purification to in‐line separative techniques. We finally describe the on‐chip analytical tools to analyze physicochemistry and phenotypes of EVs.